EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study
Title:
EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study
Author:
Zauderer, Marjorie G Szlosarek, Peter W Le Moulec, Sylvestre Popat, Sanjay Taylor, Paul Planchard, David Scherpereel, Arnaud Koczywas, Marianna Forster, Martin Cameron, Robert B Peikert, Tobias Argon, Evren Kocabaş Michaud, Neil R Szanto, Attila Yang, Jay Chen, Yingxue Kansra, Vikram Agarwal, Shefali Fennell, Dean A